thiotepa has been researched along with Renal Insufficiency in 2 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a patient with renal insufficiency (creatinine clearance, CL(cr) = 38 mL/min) who received high-dose chemotherapy with cyclophosphamide (1,500 mg/m(2) day(-1)), thiotepa (120 mg/m(2) day(-1)) and carboplatin (AUC = 5 mg min/mL day(-1)) for four consecutive days." | 7.75 | Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. ( Beijnen, JH; Ekhart, C; Huitema, AD; Kerst, JM; Rodenhuis, S, 2009) |
| "We report a patient with renal insufficiency (creatinine clearance, CL(cr) = 38 mL/min) who received high-dose chemotherapy with cyclophosphamide (1,500 mg/m(2) day(-1)), thiotepa (120 mg/m(2) day(-1)) and carboplatin (AUC = 5 mg min/mL day(-1)) for four consecutive days." | 3.75 | Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. ( Beijnen, JH; Ekhart, C; Huitema, AD; Kerst, JM; Rodenhuis, S, 2009) |
| "One patient had a retinal vein thrombosis." | 2.39 | Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. ( Baars, JW; de Glas-Vos, CW; Rodenhuis, S; Thomas, BL; van der Lelie, H; van Dijk, MA; van Oers, RH; von dem Borne, AE, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekhart, C | 1 |
| Kerst, JM | 1 |
| Rodenhuis, S | 2 |
| Beijnen, JH | 1 |
| Huitema, AD | 1 |
| van der Lelie, H | 1 |
| Baars, JW | 1 |
| van Dijk, MA | 1 |
| de Glas-Vos, CW | 1 |
| Thomas, BL | 1 |
| van Oers, RH | 1 |
| von dem Borne, AE | 1 |
1 review available for thiotepa and Renal Insufficiency
| Article | Year |
|---|---|
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 1995 |
1 other study available for thiotepa and Renal Insufficiency
| Article | Year |
|---|---|
Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Drug Interacti | 2009 |